Review
doi: 10.2337/diacare.28.10.2573.
Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider
Affiliations
- PMID: 16186303
- DOI: 10.2337/diacare.28.10.2573
Item in Clipboard
Review
Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider
Diabetes Care.
2005 Oct.
No abstract available
Comment on
-
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.Diabetes Care. 2005 Oct;28(10):2345-51. doi: 10.2337/diacare.28.10.2345. Diabetes Care. 2005. PMID: 16186261
Similar articles
-
Assessing the cardiovascular safety of diabetes therapies.N Engl J Med. 2008 Sep 11;359(11):1092-5. doi: 10.1056/NEJMp0805758. N Engl J Med. 2008. PMID: 18784098 No abstract available.
-
Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.Am J Cardiol. 2004 Jun 3;93(11A):49C-52C. doi: 10.1016/j.amjcard.2004.02.007. Am J Cardiol. 2004. PMID: 15178516 No abstract available.
-
Cardiovascular safety and diabetes drug development.Lancet. 2011 Mar 19;377(9770):977-9. doi: 10.1016/S0140-6736(10)62299-4. Lancet. 2011. PMID: 21316097 No abstract available.
-
Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus.Rev Endocr Metab Disord. 2010 Mar;11(1):21-30. doi: 10.1007/s11154-010-9130-8. Rev Endocr Metab Disord. 2010. PMID: 20195772 Review.
-
Rethinking the appraisal and approval of drugs for type 2 diabetes.BMJ. 2015 Oct 9;351:h5260. doi: 10.1136/bmj.h5260. BMJ. 2015. PMID: 26452524 Review. No abstract available.
Cited by
-
Changes in prescribing patterns and clinical outcomes in elderly diabetic patients in 2000 and 2010: analysis of a large Italian population-based study.Eur J Clin Pharmacol. 2014 Aug;70(8):965-74. doi: 10.1007/s00228-014-1678-x. Epub 2014 May 14. Eur J Clin Pharmacol. 2014. PMID: 24820766
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
